FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and concerns treating cancer in humans. That is compound of formula 
in range of daily dose from 20 mg to 1500 mg.
EFFECT: such dosing mode provides higher survival rate in patients with cancer of various localisations.
30 cl, 25 dwg, 15 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL METHODS FOR TARGETING CANCER STEM CELLS | 2011 |
|
RU2657750C1 |
| NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING AT MALIGNANT STEM CELLS | 2011 |
|
RU2571661C2 |
| PURIFIED PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE COMPOSITIONS AND METHODS OF OBTAINING AND APPLICATION THEREOF | 2010 |
|
RU2556205C2 |
| TOPOTECAN MONOHYDROCHLORIDE PENTAHYDRATE IN CRYSTALLINE FORM, CORRESPONDING COMPOSITIONS BASED ON THEM, PREPARATION AND/OR TREATMENT METHODS | 2004 |
|
RU2352572C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| CRYSTALLINE FORM OF MALEATE OF CONDENSED PYRIDINE DERIVATIVE AND METHODS FOR USE THEREOF | 2016 |
|
RU2712280C2 |
| CRYSTALLINE AND SALT FORMS OF THE TGF-βR1 INHIBITOR AND THE METHOD OF OBTAINING THEM | 2018 |
|
RU2750702C1 |
